Photopheresis Products Market By Type (Closed System, Open System), By Therapeutic Area (Cutaneous T-Cell Lymphoma, Solid Organ Transplant Rejections, Autoimmune Diseases, Graft Versus Host Diseases) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Therapeutic apheresis has been present in the healthcare system for several years, dating back to the 1950s. Currently, apheresis and its modalities are acknowledged as effective first-line treatments or adjunctive treatments for a wide range of disorders. Some common therapeutic apheresis modalities include plasmapheresis, leukapheresis, blood cell apheresis, lipid apheresis, platelet apheresis, and photopheresis. Photopheresis, also known as extracorporeal phototherapy, is gaining new popularity in the market, particularly due to its growing demand in off-label applications and greater efficacy in treating graft versus host disease and preventing organ transplant rejection.

Market Synopsis

Graft Versus Host Disease to Lead the Market in Terms of Revenue

Over half of the cost incurred in transplantation is consumed by post-transplant care costs, mainly including immunosuppressive therapies. As a majority of transplant patients develop episodes of chronic rejection, insurance companies are keen to consider management therapies such as photopheresis for patients that do not respond to conventional immunosuppressive therapies. Additionally, more than half of patients receiving allogeneic bone marrow transplants develop graft versus host disease. Photopheresis is reported to respond positively in the majority of graft-versus-host conditions and cases of organ transplant rejection. Therefore, with growing evidence in support of the efficacy of photopheresis, more recommendations from physicians and surgeons will occur, which will augment the market growth for photopheresis products.

Sustained Demand for Closed Systems to Support the Photopheresis Products Market Growth

The first system for photopheresis approved by the FDA was the UVAR by Therakos, a closed system (1988). Since then, several open and closed systems have been approved worldwide for clinical use. Open photopheresis systems use separate compartments for cell separation and photoactivation. As different steps are involved in therapy administration, there is, therefore, a high risk of contamination or patient re-infusion error. Thus, open tubes are only used in certified centers for the separate handling of blood components. However, closed systems do not face this limitation and are therefore widely used, ensuring their sustained demand and dominance in the global market.

Widespread Presence of Apheresis Centers: Ensuring the Supremacy of North America

Currently, North America dominates the global photopheresis market. The early introduction of apheresis and its subsequent modalities, as well as the widespread presence of advanced apheresis and blood processing centers, are the primary factors driving North America's prominent position on the global front. Greater affordability in the patient population, facilitated by the favorable reimbursement scenario, further contributes to the dominance of North America. However, striations in the region have resulted in a diversion of manufacturers' attention to the emerging markets of Asia Pacific and Latin America. The Asia Pacific market is mainly characterized by widening outreach of healthcare infrastructure, increasing disposable incomes in the patient population, growing awareness, and rapid approvals for advanced treatments. The global photopheresis products market is fragmented but competitive. The players are mainly identified by their product differentiation. Some prime companies engaged in this space are Terumo Corporation, Mallinckrodt Pharmaceuticals, Fresenius Kabi AG, Macopharma, Haemonetics Corporation, and others.

Periods of History and Forecast

2016 is a historic year.

2017: Base Year

2018-2026: Forecast Period

This study offers an analysis of every mentioned segment for the period from 2016 to 2026 while considering 2017 as the base year for further forecasting. Moreover, compounded annual growth rates (CAGRs) for every segment are covered and calculated for the period from 2018 to 2026.

Report Scope by Segments

This report on photopheresis products offers a quantitative assessment in terms of current and future market size, along with a qualitative analysis considering market dynamics and the competitive environment. For this purpose, the market is segmented by product types, therapeutic areas, and geographical distribution.

Type (2016-2026; millions of dollars)

  • Closed System
  • Open System

By therapeutic area (2016-2026; million US dollars),

  • Cutaneous T-cell lymphoma
  • solid organ transplant rejections
  • Autoimmune Diseases
  • Diseases of Graft Versus Host

Geography Segment (2016-2026; millions of dollars)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific (APAC)
    • China
    • Japan
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • rest of Latin America
  • Middle East and Africa (MEA)
    • GCC
    • Rest of the Middle East and Africa

The market trends prevalent in the global market for photopheresis products are scrutinized while considering the current and future roadmaps of the market. Assessment of market dynamics, such as drivers, restraints, and opportunities, provides an understanding of the market's pros and cons. This report also assesses the positions of the major market players and offers their brief profiles based on their business overviews, product portfolios relevant to the market, financial information, and key developments. The players profiled in this report include Asahi Spectra USA, Inc., Avantes BV, Cogentix Medical, Inc. (LABORIE Medical Technologies), Hamamatsu Photonics K.K., Karlstrom SE & Co. KG, Ocean Optics, Inc., Olympus Medical Systems (Olympus Corporation), SOPRO-COMEG GmbH, Smith & Nephew Plc, Stryker Corporation, and Excelitas Technologies Corp.

Key questions are answered in this report.

  • What is the current status of the photopheresis products market in 2017?
  • How will the market progress through the forecast period?
  • What are the major drivers and challenges prevalent in the global market for photopheresis products?
  • Which product type currently governs the market, and what will be its status over the forecast period?
  • Which therapeutic area is expected to witness the fastest growth during the forecast period?
  • What is the current status of the Asia-Pacific market in the global market for photopheresis products?
  • Will the market position of North America be challenged by Asia Pacific within the forecast period?
  • What is the current competitive scenario in the global market?
  • Which are the major strategies employed by the market players to strengthen their positions?

Frequently Asked Questions:

The market for Photopheresis Products is expected to reach US$ 418.56 Mn in 2026.

The Photopheresis Products market is expected to see significant CAGR growth over the coming years,at 5.5%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Haemonetics Corporation,Fresenius Kabi AG,Macopharma,Mallinckrodt Pharmaceuticals,Med Tech Solutions GmbH are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Aug 2018
Category:  Medical Devices
Report ID:   58735
Report Format:   PDF
Pages:   120
Rating:    4.7 (50)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support